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to 70 Gy concurrent with chemotherapy in a prospective cohort of poor 
risk unresectable stage III lung cancer patients.
Method: From 8/04 to 10/06, 44 unresectable stage III lung cancer 
patients seen at the Cleveland Clinic were treated with radiotherapy 
consisting of <50Gy to the primary tumor and regional lymph nodes 
followed by a boost to gross tumor for a total dose of 70 Gy. Carboplat-
in (AUC of 2) and paclitaxel (50 mg/m2) were administered concurrent-
ly with RT. At the physicians’ discretion, consolidation docetaxel (75 
mg/m2) was administered every 3 weeks for no more than 3 courses. 
Patients received 500 mg amifostine daily, divided into 2 subcutaneous 
injections, 30 to 60 minutes prior to RT. All received oral antiemetic 
and antihistamine prophylaxis prior to amifostine.
Results: Concerning patient characteristics, median age was 64.5, 
median KPS was 80, 54.5% of patients were female, 77.3% were white, 
93% were former smokers with 14% still smoking. At diagnosis, 24 pa-
tients (54.6%) were stage IIIB, with median tumor size of 3.5 cm. 64% 
of patients received >90% of planned amifostine. Median follow-up 
was 9.8 months. During, at < 90 days and at > 90 days from treatment, 
there was 2.3%, 2.3% and 4.5% grade 3 esophagitis, and 0%, 2.3% 
and 0% grade 3 pneumonitis, respectively, but no grade 4 or 5 toxicity. 
Median survival was 20.8 months and 2-year actuarial survival was 
39%. Median time-to-progression was 13.9 months, with 54.5% having 
no progression at the primary site.
Conclusions: Daily subcutaneous amifostine reduces the rates of 
esophagitis and pneumonitis expected with dose-escalated radiotherapy 
with concurrent chemotherapy, a regimen that may improve survival.
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Objective: Radiation dose is an independent prognostic factor for sur-
vival in patients with early stage non-small cell lung cancer (NSCLC). 
We hypothesized that radiation dose is also a signiﬁcant independent 
factor associated with survival in patients with stage III disease treated 
with combined radiation and chemotherapy. 
Methods: This is an Institutional Review Board approved retrospective 
study. Eligible subjects included those with stage III NSCLC registered 
in the radiation oncology database at University of Michigan Hospital 
between January 1992 and July 2004. Radiation was given using 3-
dimensional conformal technique with doses ranging from 30 to 102.9 
Gy, corresponding to a bioequivalent dose (BED) of 39 to 124.5Gy. 
Median age was 65 years (range, 36-89). There were 80 males and 67 
females. Median follow-up was 13.0 months (range, 2.7-145.9). 
Results: For patients treated with radiation alone (n=40), sequential 
chemoradiation (n=42), and concurrent chemoradiation (n=65), median 
survival was 8.6 (95% CI: 5.7-11.5), 12.8 (95% CI: 9.5-16.0) and 15.4 
(95% CI: 12.7-18.0) months, respectively (P =0 .011). Multivariate 
Cox-regression analysis showed that BED (HR=0.96, 95% CI: 0.95-
0.97, P<0.001) and administration of chemotherapy (HR=0.44, 95% 
CI: 0.28-0.70, P=0.001) were independent prognostic factors associated 
with the risk of death. T stage was marginally signiﬁcant (P=0.065). 
Age, gender, performance, weight loss and N stage were not indepen-
dent factors (P>0.05). To further study the BED effect, multivariate 
analysis was performed separately in patients treated with and without 
chemotherapy: the hazard ratios of BED for the risk of death were 0.97 
(95% CI: 0.95-0.99, P=0 .013) and 0.95 (95% CI: 0.93-0.98, P=0.001), 
respectively. BED also remained a signiﬁcant independent prognostic 
factor in patients treated with chemotherapy and radiation in the dose 
range of 60-66 Gy (HR=0.91, 95% CI: 0.84-0.99, P=0.041).
Conclusions: Radiation dose is signiﬁcantly associated with survival 
in patients with stage III NSCLC treated with combined radiation and 
chemotherapy. 
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Background: A Patterns of Care Study (PCS) was conducted to 
determine the patterns of evaluation and treatment for non-metastatic 
non-small cell lung cancer (NSCLC) in Korea.
Methods: A web-based data system for Korean Patterns of Care Study 
was developed and a national survey was conducted. Patients who 
received thoracic radiotherapy (RT) for clinical or pathologic stage I-III 
NSCLC without other malignancy in 1998 and 1999 were eligible and 
randomly selected by power allocation method.
Results: The records of 446 selected patients from 19 institutions were 
reviewed and 10 patients were excluded because of incomplete clinical 
information. Accordingly, 436 patients were the subject of this study 
with median age of 62.2 years (range, 33.1 - 88.0) and male-to-female 
ratio of 86:14. The histologies were squamous cell carcinoma in 61.2%, 
adenocarcinoma in 28.4%, large cell carcinoma in 2.3%, and NSCLC 
NOS in 8.0% of patients, respectively. Bone scan, abdominal USG or 
CT, brain CT or MRI, and PET was examined in 92.5%, 81.5%, 44.8%, 
and 26.6% of patients, respectively. The clinical stage was I in 8.9%, 
II in 12.2%, IIIA in 37.4%, and IIIB in 41.5%, respectively. Regarding 
treatment modalities, RT was used alone in 38.1%; RT combined with 
operation (OP) in 22.9%; RT combined with chemotherapy (CT) in 
27.1%; trimodalities including RT, OP, and CT in 11.9%. The median 
total dose was 59.4 Gy with daily median fraction size of 1.8 Gy and 
the percent delivered dose over 90% was achieved in 87.6%. Most of 
patients received RT in supine position (99.3%) with beam direction of 
AP/PA (95.6%) as their ﬁrst RT plan, and with photon energy of 6 MV 
(42.0%) followed by 10 MV (41.7%). The CT-based planning was used 
in 2.3 % and 32.6% for their ﬁrst and second RT plan, respectively. The 
three or more RT planning was performed in 13.5% of patients. Elec-
tive nodal irradiation was employed in 87.8% of patients and the N2 
nodal station (48.6%) was most frequently included. The 8% of patients 
received thoracic RT based on prospective protocol. 
Conclusions: This study is the ﬁrst PCF for NSCLC conducted in 
Korea. We conﬁrmed that various types of RT planning were utilized 
according to each institution, but beam delivery techniques were not 
much different in 1998 to 1999. Now another PCS is planned to evalu-
ate changing trends in national practice.
